Three new depsipeptides, fijimycins A-C (1-3), together with the known etamycin A (4), were isolated and identified from the fermentation broth of strain CNS-575, a Streptomyces sp. cultured from a marine sediment sample collected off Nasese, Fiji. The planar structures of the new fijimycins were assigned by combined interpretation of NMR and MS/MS spectroscopic data. These assignments were complicated by the fact that 1-3 occurred as complex amide conformational mixtures. The absolute configurations of the component amino acids were established using the Marfey's method. Fijimycins A-C, and etamycin A, were shown to possess significant in vitro antibacterial activity against three methicillin-resistant Staphylococcus aureus (MRSA) strains with MIC 100 values between 4 and 16 lg mL .
Introduction
Infectious disease caused by methicillin-resistant Staphylococcus aureus (MRSA) is a growing problem of potential urgency in both community and hospital settings. 1 To seek new antibiotics to treat MRSA infection, we have initiated studies to examine the secondary metabolites of marine-derived and obligate marine actinomycetes. Recent studies have shown that these microorganisms are a rich source of novel secondary metabolites. [2] [3] [4] [5] [6] The foundation of this research includes an international collaboration designed to explore the biological and natural product diversity of microorganisms cultured from marine samples collected around the islands of Fiji. As part of this program, we identified a crude fermentation extract of strain CNS-575, which showed appreciable antibiotic activity against methicillin-resistant S. aureus. This strain was identified as a Streptomyces sp. based on 16S rDNA sequence analysis. Chemical investigations, reported here, led to the discovery of the fijimycins A-C (1-3), three new depsipeptides of the etamycin class, together with etamycin A (4) itself. Herein, we report the isolation, structure elucidation, and antibiotic activities of these three new compounds (Fig. 1 ).
Results and discussion

Structure elucidation of fijimycin A (1)
Fijimycin A was isolated as a white, amorphous solid. The molecular formula was assigned as C 44 H 62 N 8 O 11 (corresponding to 18°of unsaturation) on the basis of ESI high-resolution mass spectrometry data (obsd [M+Na] + 901.4436, calcd 901.4430). The molecule was found to adopt two conformations as observed in the 1 H NMR spectrum in CDCl 3 , acetonitrile-d 3 , methanol-d 4 , acetone-d 6 , and DMSO-d 6 . NMR data acquisition at elevated and depressed temperatures did not reduce the relative composition of the conformers. However, the two conformers were sufficiently well resolved in CDCl 3 to permit assignment of the component amino acids and the peptide sequence. 2), which allowed the planar structure of fijimycin A (1) to be assigned.
The ester linkage in fijimycin A was also confirmed by methanolysis to yield the methyl ester 5, (Fig. 2 
Structure elucidation of fijimycin C (3)
Fijimycin C, a minor metabolite, was isolated as an amorphous white powder, which was assigned the molecular formula 
Antibiotic activities of fijimycins A-C
The antibiotic activities of fijimycins A-C (1-3) were examined in vitro against three MRSA strains, the hospital-associated strain (ATCC33591), the sequenced hospital-associated strain (Sanger 252), and the community-associated strain (UAMS1182). As shown in Table 4 , fijimycins A, C and etamycin A exhibited strong antibiotic activities against the three MRSA strains in the concentration range of 4-32 lg mL
À1
. However, fijimycin B showed weak inhibition against both ATCC33591 and UAMS1182, which indicated that the a-phenylsarcosine unit might be vital for significant antibacterial activity. The similar antimicrobial activities of the stereoisomers fijimycin A and etamycin A suggests that substituting D-for L-a-phenylsarcosine had little effect on the anti-MRSA activities.
Discussion
Etamycin A, also called virifogrisein I, was first isolated from cultures of a terrestrial Streptomyces species by Heinermann and Bartz in 1954. Subsequently, etamycin A was more completely characterized in 1958 by Sheehan. 9 As one of the important members of group B streptogramins, etamycin A exhibited considerable activity against gram-positive bacteria, as well as Mycobacterium tuberculosis. Etamycin found marginal use in Europe as a clinical antibacterial agent and as a feed additive in agriculture. 10 In a recent paper, the MRSA activities of etamycin were described in detail. 11 Fijimycins A-C are new members of the etamycin class of antibacterial cyclic depsipeptides.
1 H NMR studies of fijimycin A using different solvents revealed that fijimycin A exists as an equilibrium mixture of at least two or more stable conformers at room temperature. Similarly, etamycin A appeared as three distinct conformers in the NMR spectral data and the presence of conformers was not affected by changes of NMR solvent or acquisition temperature. 11 The presence of conformers might be attributed to the cis and trans isomerization of the Hyp peptide bonds.
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4. Experimental section
General experimental procedures
Optical rotations were measured using a JASCO P-2000 polarimeter with a 1 cm cell. IR spectra were acquired on a Perkin-Elmer 1600 series FTIR spectrometer. 1 H, 13 C, and 2D NMR spectroscopic data were obtained on Varian Inova 500 MHz and Varian Inova 300 MHz NMR spectrometers. HRESIMS data were recorded on a Thermo LTQ Orbitrap XL mass spectrometer, and ESIMS/MS data were recorded on a Thermo LCQ deca mass spectrometer. Low resolution LC-MS spectra were obtained on a Hewlett-Packard HP1100 integrated LC-MS system with a reversed-phase C18 column (Agilent, 4.6 mm Â 100 mm, 5 lm) at a flow rate of 0.7 mL min
À1
. Reversed phase HPLC separations were performed using a semipreparative C 18 Phenomenex Luna 5 lm (10 mm Â 250 mm) column with a CH 3 CN/H 2 O gradient solvent system. Preparative HPLC separations were performed using a Waters model 4000 system with a UV variable-wavelength detector, monitoring at 254 nm, and employing a C 18 Nova-Pak 6 lm, 60 Å (40 mm Â 300 mm) column. Amino acid standards of known configurations used to determine the absolute stereochemistry of fijimycins were purchased from Sigma-Aldrich, INC.
Bacterial isolation and identification
Strain CNS-575 was obtained from a marine sediment sample collected at a depth of ca. 0.5 m from the Nasese shoreline, Viti Levu, Fiji. The sediment was first heat-shocked at 55°C for 6 min and then directly plated into medium M1 (10 g starch, 4 g yeast extract, 2 g peptone, 1 L filtered seawater) supplemented with 0.5 lg mL À1 rifampicin and 100 lg L À1 cycloheximide as previously described. 15 The strain was identified as a Streptomyces sp.
based on 16S rRNA gene sequence analysis (accession number GQ325662) and shares greatest similarity (99.2%) with the marine sponge-derived species Streptomyces haliclonae (accession number AB473556).
Fermentation and extraction
Streptomyces sp., strain CNS-575, was cultured at 27°C for 6 days with shaking at 215 rpm in 40 Â 1 L volumes of the liquid medium (A1Bfe+C) [composed of 10 g starch, 4 g yeast extract, 2 g peptone, 1 g CaCO 3 , 40 mg Fe 2 (SO 4 ) 3 Á4H 2 O, 100 mg KBr, per 1 L seawater]. Pre-sterilized Amberlite XAD-7 resin (20 g L À1 ) was added at the end of the fermentation period to adsorb extracellular secondary metabolites. The culture and resin were shaken at low speed for two additional hours. The resin and most of the cell mass were collected by filtration through cheesecloth and washed with DI water to remove salts. The resin, cell mass, and cheesecloth were then soaked for 2 h in acetone, after which the acetone extract was filtered and the solvent removed under vacuum to give 8.6 g of solid material from a 40 L culture.
Isolation of fijimycins A-C (1-3)
The crude acetone extract (8.6 g) was fractionated by Si gel open column chromatography eluting with a step gradient from 10% ethyl acetate in isooctane to 15% methanol in ethyl acetate to give nine fractions. Fraction six (3.9 g), which contained the depsipeptides, was subjected to reversed-phase HPLC (Phenomenex Luna C 18 , 10 mm Â 250 mm, 5 lm) with 65% aqueous CH 3 CN at 2.5 mL min À1 flow rate and UV detection at 254 nm. Fijimycins A (1, 65 mg), B (2, 9.6 mg), and C (3, 3.2 mg) were eluted at 27.7, 40.5, and 17.5 min, respectively. 
Fijimycin
Acid hydrolysis and Marfey analysis
Hydrolysis of fijimycins A, B, and C (0.5 mg each) was achieved, in separate experiments, by the addition of 0.5 mL of 6 N HCl at 115°C for 12 h. The hydrolysate was evaporated to dryness and resuspended in water (1 mL) and again evaporated to dryness under a stream of N 2 to remove traces of HCl. The solvent was removed under vacuum and 0.4 mL NaHCO 3 (100 lL) and 
Methanolysis of fijimycin A (1)
To 1.5 mg of 1 was added 1.5 mL of a 0.5 N NaOMe solution, and the reaction was stirred at room temperature for 2 h under nitrogen. LC-MS analysis indicated the complete conversion of the starting material to the desired methyl ester. The mixture was neutralized by adding 1 mL saturated NH 4 Cl, and the resulting mixture was 
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